dementia

With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doses

A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients. It is a tale  that could push Congress to allow Medicare to negotiate drug prices. Reuters reports that Biogen, which sells the controversial medication it calls Aduhelm, is [...]

By |2021-09-01T15:11:40-04:00September 1st, 2021|dementia|0 Comments

New Ethics Standards For Docs Who Care for People With Dementia

The ethics committee of the American Academy of Neurology has updated its guidelines for caring for people with dementia and their families. The statement could accelerate an important shift in the way physicians treat patients with dementia. The guidelines highlight the need for physicians to recognize patient autonomy and the key role played by family caregivers. And they require doctors [...]

By |2021-08-19T11:08:50-04:00August 19th, 2021|dementia|0 Comments

Will Medicare Pay For The New Alzheimer’s Drug?

Last month, The Food and Drug Administration (FDA) approved a controversial new drug to treat people with Alzheimer’s disease. But even though the FDA allowed the drug to be sold, Medicare is not required to pay for it. And yesterday, the Centers for Medicare & Medicaid Services (CMS) began a process to determine whether Medicare will establish a national coverage [...]

By |2021-07-13T13:57:06-04:00July 13th, 2021|dementia|0 Comments

What Does FDA’s Approval Of A New Alzheimer’s Drug Mean?

In a highly controversial decision, the FDA gave accelerated approval to the first drug that could slow the progression of Alzheimer’s disease. But the approval does not say the FDA thinks the drug actually will treat the disease. Rather, FDA carefully states that the drug, with the chemical name aducanumab and the brand name Aduhelm, reduces a substance on the [...]

By |2021-06-07T17:50:37-04:00June 7th, 2021|dementia|5 Comments

The Anti-Alzheimer’s BOLD Act Isn’t. But It Could Be A Step In The Right Direction

Last week, President Trump signed into law the BOLD Infrastructure for Alzheimer’s Act, a measure aimed at building a public health model to fight Alzheimer’s disease and other dementias. The law would authorize up to $100 million over five years to improve public education, support health and social service agencies’ dementia initiatives, and collect and disseminate data about cognitive decline. [...]

By |2019-01-09T11:00:47-05:00January 9th, 2019|dementia|0 Comments

Are We Getting Closer To A Cheap, Simple Alzheimer’s Test? What Would It Mean?

Have you seen the stories about new tests for Alzheimer’s Disease that supposedly are just around the corner? The claims: A simple blood test, an eye test, even a smell test that could show that you are at high risk for Alzheimer’s decades before you develop symptoms. They are promising, scary, and--so far--premature. Sadly, we’ve seen this movie before. Like [...]

By |2017-08-23T07:59:12-04:00August 23rd, 2017|dementia|0 Comments

Getting Real About An Alzheimer’s Cure

For decades, people have been hoping for the magic bullet that will prevent, cure, or even slow the progression of Alzheimer’s Disease or other dementias. Yet, despite small hints of progress-- and billions of dollars in research--there is no drug, and no app or game, that can successfully treat these diseases. This year, results of these efforts have been decidedly [...]

By |2016-09-07T15:38:20-04:00September 7th, 2016|dementia|0 Comments

Should Drugmakers Be Allowed To Avoid Taxes On Their Profits From An Alzheimer’s Drug?

In one of the worst ideas I’ve heard in a long time, two congressmen have introduced a bill to make profits from the sale of certain anti-Alzheimer’s drugs tax free for seven years.  The measure, sponsored by representatives Patrick Murphy (D-FL) and Mike Fitzpatrick (R-PA), may be well-intentioned, but it would provide a multi-billion dollar windfall to pharmaceutical companies. There [...]

By |2016-07-08T12:25:35-04:00July 8th, 2016|dementia|0 Comments

Congress OK’s Big Boost In Alzheimer’s Research But Offers Little To Help Those Who Already Have The Disease

Just before leaving town for the year, Congress passed a budget that increased funding for Alzheimer’s research by 60 percent, but, as usual, provided little new money for programs that help those who have the disease, other frail elders, or their caregivers. Over the past six years, funding for most of these much-needed programs has not even kept up with [...]

By |2015-12-28T15:48:52-05:00December 28th, 2015|dementia, Federal senior services programs|0 Comments